




Inventor:
Title:
Docket No.:
Sheet 1 of 51

Schwiebert et al.
Methods and Compositions for P2X
Receptor Calcium Entry Channels and
Other Calcium Entry Mechanisms
21085.0044U3
REPLACEMENT SHEET



Zinc benefits to CF lung therapy

- Rescue of Cl^- and fluid secretion
- Attenuation of Na^+ hyperabsorption
- Potentiation of ATP-, Na^+ - and Ca^{2+} -dependent ciliary beat?




FIG.1B

Zinc as an anti-inflammatory for CF and other airway diseases such as asthma and common cold

- Zinc in a solution-based formulation enters the cell as free ionic zinc and inhibits Zinc NFkappaB activation




FIG.2A

Zinc as an anti-microbial for CF and other airway and GI diseases caused by bacterial pathogens

- Zinc in a solution-based formulation competitively inhibits the metal scavenging system of a bacterium.




FIG.2B




FIG.3A

Zinc benefits to PKD therapy and therapy of other renal hypertensive disorders

- Direct inhibition of Na^+ hyperabsorption
- Stimulation of P2XR Ca^{2+} entry channels "alternative" to ciliium-derived Ca^{2+} entry




FIG.3B

Normal Insulin Secretion in a Pancreatic Islet β Cell




FIG.4A

"Controlled" Diabetic β Cell




FIG.4B




FIG.5A-1




FIG.5A-2




FIG.5B




FIG. 5C




FIG. 5D




FIG.5F




FIG.5E




FIG. 6A




FIG. 6B




FIG.7A




FIG.7B




FIG.8A




FIG.8B




FIG.8C




FIG.8D




FIG.8E

Transepithelial Nasal Potential Difference Values of Control, $\Delta 508$ CF and Bitransgenic CF Mice

| | Control | | CF | | Bitransgenic CF | |
|--|------------------------------|----|-----------------------------------|----|-----------------------------------|----|
| | Cftr(+/-) | n | Cftr($\Delta F508/\Delta F508$) | n | Cftr(-/-) | n |
| Starting point | -18.7 \pm 6.5 | 19 | -26.3 \pm 7.2 [*] | 11 | -26.1 \pm 3.8 [*] | 14 |
| Low [Cl ⁻] _e (Na ⁺ ; pH:7.3) | -5.5 \pm 1.5 | 8 | +3.7 \pm 1.6 [*] | 3 | +4.8 \pm 2.5 [*] | 7 |
| ATP + ZnCl ₂ (NMDG; pH:7.9) | -4.7 \pm 1.8 | 6 | -4.0 \pm 2.0 | 3 | -3.8 \pm 2.0 | 12 |
| Low [Cl ⁻] _e (Na ⁺ ; pH:7.9) | -4.8 \pm 2.0 | 6 | +5.4 \pm 2.8 [*] | 7 | +6.7 \pm 4.0 [*] | 3 |
| ATP + ZnCl ₂ (NMDG; pH:7.9) | -6.0 \pm 1.4 | 2 | -9.4 \pm 1.6 ^{*#} | 8 | -9.7 \pm 3.1 ^{*&} | 3 |
| Low [Cl ⁻] _e (NMDG; pH:7.9) | -4.8 \pm 3.3 | 5 | | | +5.8 \pm 1.9 [*] | 4 |
| ATP + ZnCl ₂ (NMDG; pH:7.9) | -5.7 \pm 1.2 | 3 | | | -10.2 \pm 1.3 ^{*&} | 6 |
| ATP alone (NMDG; pH:7.9) | | | | | -2.3 \pm 1.0 [§] | 4 |
| Low [Cl ⁻] _e (NMDG; no added Ca ²⁺ ; pH:7.9) | -7.3 \pm 0.6 | 3 | | | +6.0 \pm 0.8 [*] | 4 |
| ATP + ZnCl ₂ (NMDG; no added Ca ²⁺ ; pH:7.9) | -1.3 \pm 0.6 ^{\$} | 3 | | | -2.0 \pm 1.2 ^{\$} | 4 |

FIG.8F




FIG. 9A




FIG. 9B




FIG. 9C





FIG. 9D






FIG. 10B




FIG.10C





FIG.11A



FIG.11B



E. coli.

FIG. 11C





FIG.12A





FIG.12B




FIG. 13A




FIG.13B-1




FIG.13B-2




FIG.14A




FIG.14B




FIG.15A




FIG. 15B

| Modified Saline** (pH 7.3) | | | Modified Saline (pH 7.3) + 15 mM Glucose | | |
|----------------------------|--------------|------------|--|--------------|------------|
| Time | Absorbance | [Insulin] | Time | Absorbance | [Insulin] |
| 15" | 0.682 ± 0.03 | ~3.0 ng/ml | 15" | 1.070 ± 0.05 | ~5.0 ng/ml |
| 15' | 0.765 ± 0.04 | 3.25 | 15' | 0.957 ± 0.07 | 4.5 |
| 30' | 0.794 ± 0.06 | 3.5 | 30' | 1.204 ± 0.10 | 5.5 |
| 60' | 1.794 ± 0.09 | 9.0 | 60' | 2.065 ± 0.05 | 11.0 |
| 120' | 1.137 ± 0.05 | 5.0 | 120' | 1.105 ± 0.18 | 5.0 |

*Generous gift of Dr. Chris Newgard at Duke.

**Modified saline is 0 Na (substituted fully by NMDG), 0 Mg, and 3 mM Ca.

| Standard Curve | |
|----------------|------------|
| Absorbance | [Insulin] |
| 0.248 | 0.0 |
| 0.226 | 0.2 ng/ml |
| 0.280 | 0.5 ng/ml |
| 0.377 | 1.0 ng/ml |
| 0.559 | 2.0 ng/ml |
| 1.10 | 5.0 ng/ml |
| 1.91 | 10.0 ng/ml |
| ~3.0 | ~20 ng.ml |

FIG.16A




FIG.16B





FIG.17A





FIG.17B




FIG.18A





FIG. 18B






FIG.19B




FIG.19C-1




FIG.19C-2

| <u>Designation</u> | <u>Mode of Stimulation</u> | <u>Epithelial Polarity</u> |
|---|---|----------------------------|
| Store-operated Ca^{2+} channels (SOCs) or I _{CRAC} | ER store depletion | Unclear |
| TRP channels | ER store depletion (partial) Alkaline extracellular pH (partial) | Apical & Basolateral |
| P2X receptor Ca^{2+} entry channels | Extracellular zinc and ATP | Apical & Basolateral |
| ECaC or CAT (<i>Related to TRPs</i>) | ER store depletion | Apical |
| Ca^{2+} -permeable non-selective cation channel (NSCC) | Stretch-activated | Apical |

FIG.19D




FIG. 20A




FIG. 20B




FIG.20C




FIG. 20D




FIG.20E